Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein

Virology

Volumn 484, Issue , 2015, Pages 259-264

  Albariño, César G ^a   Wiggleton Guerrero, Lisa ^a   Lo, Michael K ^a   Nichol, Stuart T ^a   Towner, Jonathan S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PROTEIN VP40; ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS RNA;

AFRICA; ARTICLE; CONTROLLED STUDY; EBOLAVIRUS; EPIDEMIC; GENE CONTROL; GENOME ANALYSIS; HUMAN; MAKONA VIRUS; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE GENETICS; RNA SEQUENCE; SEQUENCE ANALYSIS; SPECIES DIVERSITY; VIRUS GENOME; VIRUS ISOLATION; VIRUS RECOMBINANT; BIOSYNTHESIS; DNA SEQUENCE; DRUG SCREENING; EBOLA HEMORRHAGIC FEVER; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; PROCEDURES; REPORTER GENE; STAINING; VIROLOGY;

EBOLA VIRUS;

AFRICA, WESTERN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; EBOLAVIRUS; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MOLECULAR SEQUENCE DATA; REVERSE GENETICS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; STAINING AND LABELING;

EID: 84932640785     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.06.013     Document Type: Article

References (47)

1. Albariño C.G., Shoemaker T., Khristova M.L., Wamala J.F., Muyembe J.J., Balinandi S., Tumusiime A., Campbell S., Cannon D., Gibbons A., Bergeron E., Bird B., Dodd K., Spiropoulou C., Erickson B.R., Guerrero L., Knust B., Nichol S.T., Rollin P.E., Ströher U. Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012. Virology 2013, 442:97-100.
2. Albariño C.G., Uebelhoer L.S., Vincent J.P., Khristova M.L., Chakrabarti A.K., McElroy A., Nichol S.T., Towner J.S. Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate. Virology 2013, 446:230-237.
3. Baize S. Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus. Curr. Opin. Virol. 2015, 10C:70-76.
4. Baize S., Pannetier D., Oestereich L., Rieger T., Koivogui L., Magassouba N., Soropogui B., Sow M.S., Keita S., De Clerck H., Tiffany A., Dominguez G., Loua M., Traore A., Kolie M., Malano E.R., Heleze E., Bocquin A., Mely S., Raoul H., Caro V., Cadar D., Gabriel M., Pahlmann M., Tappe D., Schmidt-Chanasit J., Impouma B., Diallo A.K., Formenty P., Van Herp M., Günther S. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 2014, 371:1418-1425.
5. CDC Update: Ebola virus disease epidemic - west Africa. MMWR Morb. Mortal. Wkly. Rep. 2015, 64:109-110.
6. Chambers R., Takimoto T. Trafficking of Sendai virus nucleocapsids is mediated by intracellular vesicles. PLoS One 2010, 5:e10994.
7. Crance J.M., Scaramozzino N., Jouan A., Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 2003, 58:73-79.
8. Dixon M.G., Schafer I.J., Centers for Disease, C., Prevention Ebola viral disease outbreak - West Africa. MMWR Morb. Mortal. Wkly. Rep. 2014, 63:548-551.
9. Dowall S.D., Matthews D.A., Garcia-Dorival I., Taylor I., Kenny J., Hertz-Fowler C., Hall N., Corbin-Lickfett K., Empig C., Schlunegger K., Barr J.N., Carroll M.W., Hewson R., Hiscox J.A. Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity. Genome Biol. 2014, 15:540.
10. Duprex W.P., Collins F.M., Rima B.K. Modulating the function of the measles virus RNA-dependent RNA polymerase by insertion of green fluorescent protein into the open reading frame. J. Virol. 2002, 76:7322-7328.
11. Ebihara H., Groseth A., Neumann G., Kawaoka Y., Feldmann H. The role of reverse genetics systems in studying viral hemorrhagic fevers. Thromb. Haemost. 2005, 94:240-253.
12. Ebihara H., Theriault S., Neumann G., Alimonti J.B., Geisbert J.B., Hensley L.E., Groseth A., Jones S.M., Geisbert T.W., Kawaoka Y., Feldmann H. In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J. Infect. Dis. 2007, 196(Suppl. 2):S313-S322.
13. Enterlein S., Volchkov V., Weik M., Kolesnikova L., Volchkova V., Klenk H.D., Muhlberger E. Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J. Virol. 2006, 80:1038-1043.
14. Falzarano D., Feldmann H. Possible leap ahead in filovirus therapeutics. Cell Res. 2014, 24:647-648.
15. Feldmann H., Sanchez A., Geisbert T.W. Filoviridae: marburg and Ebola viruses. Fields Virology 2013, 923-956. Lippincott, Williams and Wilkins, Philadelphia. 6th ed. D.P.M. Knipe (Ed.).
16. Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. J. Gen. Virol. 2014, 95:1619-1624.
17. Gire S.K., Goba A., Andersen K.G., Sealfon R.S., Park D.J., Kanneh L., Jalloh S., Momoh M., Fullah M., Dudas G., Wohl S., Moses L.M., Yozwiak N.L., Winnicki S., Matranga C.B., Malboeuf C.M., Qu J., Gladden A.D., Schaffner S.F., Yang X., Jiang P.P., Nekoui M., Colubri A., Coomber M.R., Fonnie M., Moigboi A., Gbakie M., Kamara F.K., Tucker V., Konuwa E., Saffa S., Sellu J., Jalloh A.A., Kovoma A., Koninga J., Mustapha I., Kargbo K., Foday M., Yillah M., Kanneh F., Robert W., Massally J.L., Chapman S.B., Bochicchio J., Murphy C., Nusbaum C., Young S., Birren B.W., Grant D.S., Scheiffelin J.S., Lander E.S., Happi C., Gevao S.M., Gnirke A., Rambaut A., Garry R.F., Khan S.H., Sabeti P.C. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 2014, 345:1369-1372.
18. Groseth A., Marzi A., Hoenen T., Herwig A., Gardner D., Becker S., Ebihara H., Feldmann H. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog. 2012, 8:e1002847.
19. Hartman A.L., Bird B.H., Towner J.S., Antoniadou Z.A., Zaki S.R., Nichol S.T. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of Ebola virus. J. Virol. 2008, 82:2699-2704.
20. Hartman A.L., Dover J.E., Towner J.S., Nichol S.T. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 2006, 80:6430-6440.
21. Hartman A.L., Towner J.S., Nichol S.T. Ebola and marburg hemorrhagic fever. Clin. Lab. Med. 2010, 30:161-177.
22. Hoenen T., Feldmann H. Reverse genetics systems as tools for the development of novel therapies against filoviruses. Expert Rev. Anti-Infect. Ther. 2014, 12:1253-1263.
23. Hoenen T., Groseth A., Callison J., Takada A., Feldmann H. A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. Antiviral Res. 2013, 99:207-213.
24. Hoenen T., Groseth A., de Kok-Mercado F., Kuhn J.H., Wahl-Jensen V. Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res. 2011, 91:195-208.
25. Hoenen T., Shabman R.S., Groseth A., Herwig A., Weber M., Schudt G., Dolnik O., Basler C.F., Becker S., Feldmann H. Inclusion bodies are a site of ebolavirus replication. J. Virol. 2012, 86:11779-11788.
26. Johnson K.M. Ebola haemorrhagic fever in Zaire, 1976. Bull. World Health Organ. 1978, 56:271-293.
27. Johnson K.M., Lange J.V., Webb P.A., Murphy F.A. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 1977, 1:569-571.
28. Kim J.H., Lee S.R., Li L.H., Park H.J., Park J.H., Lee K.Y., Kim M.K., Shin B.A., Choi S.Y. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 2011, 6:e18556.
29. Leroy E.M., Gonzalez J.P., Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin. Microbiol. Infect. 2011, 17:964-976.
30. Lo M.K., Nichol S.T., Spiropoulou C.F. Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening. Antiviral Res. 2014, 106:53-60.
31. Martinez M.J., Volchkova V.A., Raoul H., Alazard-Dany N., Reynard O., Volchkov V.E Role of VP30 phosphorylation in the Ebola virus replication cycle. J. Infect. Dis. 2011, 204(Suppl. 3):S934-S940.
32. Morrey J.D., Smee D.F., Sidwell R.W., Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 2002, 55:107-116.
33. Neumann G., Feldmann H., Watanabe S., Lukashevich I., Kawaoka Y. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J. Virol. 2002, 76:406-410.
34. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991, 108:193-199.
35. Panchal R.G., Kota K.P., Spurgers K.B., Ruthel G., Tran J.P., Boltz R.C., Bavari S. Development of high-content imaging assays for lethal viral pathogens. J. Biomol. Screen. 2010, 15:755-765.
36. Panchal R.G., Reid S.P., Tran J.P., Bergeron A.A., Wells J., Kota K.P., Aman J., Bavari S. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antiviral Res. 2012, 93:23-29.
37. Pyrc K., Bosch B.J., Berkhout B., Jebbink M.F., Dijkman R., Rottier P., van der Hoek L. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob. Agents Chemother. 2006, 50:2000-2008.
38. Schmidt K.M., Schumann M., Olejnik J., Krahling V., Muhlberger E. Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread. J. Infect. Dis. 2011, 204(Suppl. 3):S861-S870.
39. Schudt G., Kolesnikova L., Dolnik O., Sodeik B., Becker S. Live-cell imaging of Marburg virus-infected cells uncovers actin-dependent transport of nucleocapsids over long distances. Proc. Natl. Acad. Sci. USA 2013, 110:14402-14407.
40. Silin D., Lyubomska O., Ludlow M., Duprex W.P., Rima B.K. Development of a challenge-protective vaccine concept by modification of the viral RNA-dependent RNA polymerase of canine distemper virus. J. Virol. 2007, 81:13649-13658.
41. Smee D.F., McKernan P.A., Nord L.D., Willis R.C., Petrie C.R., Riley T.M., Revankar G.R., Robins R.K., Smith R.A. Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Antimicrob. Agents Chemother. 1987, 31:1535-1541.
42. Stadler T., Kuhnert D., Rasmussen D.A., du Plessis L. Insights into the early epidemic spread of ebola in sierra leone provided by viral sequence data. PLoS Curr. 2014, 6. Oct 6. Edition 1. 10.1371/currents.outbreaks.02bc6d927ecee7bbd33532ec8ba6a25f.
43. Theriault S., Groseth A., Artsob H., Feldmann H. The role of reverse genetics systems in determining filovirus pathogenicity. Arch. Virol. Suppl. 2005, 19:157-177.
44. Towner J.S., Paragas J., Dover J.E., Gupta M., Goldsmith C.S., Huggins J.W., Nichol S.T. Generation of eGFP expressing recombinant Zaire Ebola virus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 2005, 332:20-27.
45. Tsuda Y., Hoenen T., Banadyga L., Weisend C., Ricklefs S.M., Porcella S.F., Ebihara H. An Improved reverse genetics system to overcome cell-type-dependent Ebola virus genome plasticity. J. Infect. Dis. 2015, Mar 24. pii: jiu681. [Epub ahead of print].
46. Uebelhoer L.S., Albariño C.G., McMullan L.K., Chakrabarti A.K., Vincent J.P., Nichol S.T., Towner J.S. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antiviral Res. 2014, 106:86-94.
47. Volchkov V.E., Volchkova V.A., Muhlberger E., Kolesnikova L.V., Weik M., Dolnik O., Klenk H.D. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001, 291:1965-1969.